Human Immunology News Volume 11.39 | Oct 3 2023

    0
    14








    2023-10-03 | HIN 11.39


    Human Immunology News by STEMCELL Technologies
    Vol. 11.39 – 3 October, 2023
    TOP STORY

    The Local Microenvironment Drives Activation of Neutrophils in Human Brain Tumors

    The authors investigated neutrophils in tumor tissue of glioma and brain metastasis patients, with matched peripheral blood, and described the first in-depth analysis of neutrophil phenotypes and functions in these tissues.
    [Cell]

    Full ArticleGraphical Abstract
    PUBLICATIONSRanked by the impact factor of the journal

    Deletion of the Inhibitory Co-Receptor CTLA4 Enhances and Invigorates Chimeric Antigen Receptor T Cells

    Scientists investigated whether disruption of the co-inhibitory receptors CTLA4 or PD-1 could restore CART function. CRISPR-Cas9-mediated deletion of CTLA4 in preclinical models of leukemia and myeloma improved CAR T cell proliferation and anti-tumor efficacy.
    [Immunity]

    Full ArticleGraphical Abstract

    A T Cell Receptor Targeting a Recurrent Driver Mutation in FLT3 Mediates Elimination of Primary Human Acute Myeloid Leukemia In Vivo

    Investigators identified a T cell receptor reactive to the recurrent D835Y driver mutation in the FMS-related receptor tyrosine kinase 3 tyrosine kinase domain (TCRFLT3D/Y). TCRFLT3D/Y-redirected T cells selectively eliminated primary human AML cells harboring the FLT3D835Y mutation in vitro and in vivo.
    [Nature Cancer]

    Full ArticlePress Release

    Modulation of Lytic Molecules Restrain Serial Killing in γδ T Lymphocytes

    Researchers explored, using live single-cell imaging, the cytotoxic functions of γδ T cells upon interactions with tumor target cells with high temporal and spatial resolution.
    [Nature Communications]

    Full Article

    Epitope-Engineered Human Hematopoietic Stem Cells Are Shielded from CD123-Targeted Immunotherapy

    Scientists demonstrated that epitope-engineered HSPCs were shielded from CD123-targeted immunotherapy but remained functional, while CD123-deficient HSPCs displayed a competitive disadvantage.
    [Journal Of Experimental Medicine]

    Full Article
    Graphical
    Abstract

    Characteristics and Anatomic Location of PD-1+TCF1+ Stem-Like CD8 T Cells in Chronic Viral Infection and Cancer

    Researchers found that CD8 tumor-infiltrating lymphocytes in both murine and human tumors exhibited overall similar phenotypic and transcriptional characteristics compared to corresponding subsets in the spleen of chronically infected mice.
    [Proceedings Of The National Academy Of Sciences Of The United States Of America]

    Full Article

    Widespread Impact of Immunoglobulin V-Gene Allelic Polymorphisms on Antibody Reactivity

    By analyzing >1,000 publicly available antibody-antigen structures, investigators showed that many V-gene allelic polymorphisms in antibody paratopes were determinants for antibody binding activity.
    [Cell Reports]

    Full ArticleGraphical Abstract

    Signaling Dynamics Distinguish High- and Low-Priority Neutrophil Chemoattractant Receptors

    Different chemoattractants could drive qualitatively different modes of migration even though their receptors couple to the same Gαi family of G proteins. The authors used live-cell imaging to demonstrate that the responses differed in their signaling dynamics.
    [Science Signaling]

    Abstract

    Human Skin CD141+ Dendritic Cells Regulate Cutaneous Immunity via the Neuropeptide Urocortin-2

    Investigators demonstrated CD141+ dermal dendritic cells (DCs) and CD141hiVitD3 monocyte-derived DCs shared key immunological features including cell surface markers, reduced T cell stimulation, IL-10 production, and a common transcriptomic signature.
    [iScience]

    AbstractFull Article
    Find the Right Antibodies for Your Stem Cell Research. Learn More
    REVIEWS

    Challenges in Developing Personalized Neoantigen Cancer Vaccines

    Scientists focus on the key obstacles pertaining to vaccine design and tumor environment that remain to be overcome in order to unleash the true potential of neoantigen vaccines in cancer therapy.
    [Nature Reviews Immunology]

    Abstract

    Multifaceted Role of mTOR (Mammalian Target of Rapamycin) Signaling Pathway in Human Health and Disease

    The authors discuss the developments for the therapeutic targeting of mTOR signaling with improved anticancer efficacy for the benefit of cancer patients in clinics.
    [Signal Transduction And Targeted Therapy]

    Full Article
    INDUSTRY AND POLICY NEWS

    Pioneers of mRNA COVID Vaccines Win Medicine Nobel

    This year’s Nobel Prize in Physiology or Medicine has been awarded to biochemist Katalin Karikó and immunologist Drew Weissman for discoveries that enabled the development of mRNA vaccines against COVID-19.
    [Nature News]

    Editorial

    AbbVie Axes Caribou CAR-T Deal, Continuing Cascade of Punted Cancer Pacts

    AbbVie has decided it can do without Caribou Biosciences. The Big Pharma is terminating its off-the-shelf CAR-T pact with the biotech, depriving Caribou of the chance to pocket up to $350 million in milestones per program.
    [Fierce Biotech]

    Editorial
    FEATURED EVENT

    Till & McCulloch Meetings 2023

    October 23 – 25, 2023
    Toronto, Ontario, Canada

    > See All Events

    JOB OPPORTUNITIES

    Postdoctoral Position – Immunology

    University of Texas MD Anderson Cancer Center – Houston, Texas, United States

    Faculty Positions – Cell Therapies

    The University of British Columbia – Vancouver, British Columbia, Canada

    Scientific Director – Intramural Research Program

    National Cancer Institute – Bethesda, Maryland, United States

    Research Associate – Tissue Immunology

    Imperial College London – London, England, United Kingdom

    Assistant/Associate/Full Professor – Director of Allergy and Immunology Division

    McGill University – Montreal, Quebec, Canada

    > See All Jobs

    Submit an article, publication, job or event
    Brought to you by
    stemcell-logo-for newsletter-2
    Human Immunology News Twitter